EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PD-L1 in Merkel Cell Carcinoma: From Tumor Microenvironment to Pathological Interpretation

Ludovica Pepe, Vincenzo Fiorentino iD, Mario Della Mura iD, Alessandro Rizzo iD, Mariacarmela Santarpia, Antonio Ieni iD, Gerardo Cazzato iD, Maria Lentini

International Journal of Molecular Sciences · 23.09.2026 · 27 (19) · 8460

DOI: 10.3390/ijms27198460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.09.2026. Verfasst von Ludovica Pepe und 7 weiteren Autor:innen. Beteiligte Einrichtung: PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical Sciences, Dental Sciences and Morpho-Functional Imaging, Univer…. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, B7-H1 Antigen, Tumor Microenvironment, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma in which Merkel cell polyomavirus (MCPyV) oncoproteins and ultraviolet-induced mutations provide distinct sources of tumor immunogenicity. This narrative review examines the biological determinants, immunohistochemical assessment, and prognostic and therapeutic relevance of programmed death ligand 1 (PD-L1) in MCC, linking tumor immunobiology to pathological interpretation. PD-L1 expression on tumor and immune cells is often concentrated at tumor–immune interfaces, consistent with interferon-γ-driven adaptive immune resistance. Reported associations with survival and treatment response vary across studies, partly reflecting differences in tissue sampling, assays, scoring compartments, and treatment context. Immune checkpoint blockade can produce durable responses in both PD-L1-positive and PD-L1-negative tumors, while baseline PD-L1 expression alone is not a validated criterion for treatment selection. Resistance mechanisms and emerging biomarkers are discussed alongside viral status, T-cell architecture, antigen-presentation defects, and alternative immune checkpoints. A reporting framework should emphasize specimen characteristics, assay documentation, separate assessment of PD-L1 expression in tumor and immune cells, and spatial heterogeneity. Interpreting PD-L1 within this biological and pathological context supports informative reporting and highlights the potential of integrated spatial biomarkers to improve understanding of immune responsiveness in MCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellB7-H1 AntigenTumor MicroenvironmentSkin NeoplasmsHumansBiomarkers, TumorMerkel cell polyomavirusPrognosisImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Merkel cell carcinomaMerkel cell polyomavirusPD-1PD-L1immune checkpoint inhibitorsimmunohistochemistrypathology reportingtumor microenvironment

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical Sciences, Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.
  • Department of Human Pathology of Adults and Developmental Age "Gaetano Barresi", Division of Pathology, University of Messina, 98125 Messina, Italy.
  • Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
  • S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
  • Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy.

ORCID-Profile: Vincenzo Fiorentino, Mario Della Mura, Alessandro Rizzo, Antonio Ieni, Gerardo Cazzato

Zitieren

APA

Pepe, L., Fiorentino, V., Della Mura, M., Rizzo, A., Santarpia, M., Ieni, A., Cazzato, G., & Lentini, M. (2026). PD-L1 in Merkel Cell Carcinoma: From Tumor Microenvironment to Pathological Interpretation. International Journal of Molecular Sciences, 27(19), 8460. https://doi.org/10.3390/ijms27198460

Vancouver

Pepe L, Fiorentino V, Della Mura M, Rizzo A, Santarpia M, Ieni A, et al. PD-L1 in Merkel Cell Carcinoma: From Tumor Microenvironment to Pathological Interpretation. International Journal of Molecular Sciences. 2026;27(19):8460. doi:10.3390/ijms27198460

BibTeX
@article{Pepe2026,
  author = {Pepe, Ludovica and Fiorentino, Vincenzo and Della Mura, Mario and Rizzo, Alessandro and Santarpia, Mariacarmela and Ieni, Antonio and Cazzato, Gerardo and Lentini, Maria},
  title = {PD-L1 in Merkel Cell Carcinoma: From Tumor Microenvironment to Pathological Interpretation},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {19},
  pages = {8460},
  doi = {10.3390/ijms27198460}
}
Kostenlos starten →